Therapeutic antibody glycosylation impacts antigen recognition and immunogenicity.

Wolf, Babette; Piksa, Mateusz; Beley, Isabelle; Patoux, Agnes; Besson, Thierry; Cordier, Valerie; Voedisch, Bernd; Schindler, Patrick; Stöllner, Daniela; Perrot, Ludovic; von Gunten, Stephan; Brees, Dominique; Kammüller, Michael (2022). Therapeutic antibody glycosylation impacts antigen recognition and immunogenicity. Immunology, 166(3), pp. 380-407. Wiley-Blackwell 10.1111/imm.13481

Preview

Text Immunology_-_2022_-_Wolf_-_Therapeutic_antibody_glycosylation_impacts_antigen_recognition_and_immunogenicity.pdf - Accepted Version Available under License Publisher holds Copyright. Download (2MB) | Preview

In this study we show that glycosylation is relevant for immune recognition of therapeutic antibodies, and that defined glycan structures can modulate immunogenicity. Concerns regarding immunogenicity arise from the high heterogeneity in glycosylation that is difficult to control and can deviate from human glycosylation if produced in non-human cell lines. While non-human glycosylation is thought to cause hypersensitivity reactions and immunogenicity, less is known about effects of Fc-associated glycan structures on immune cell responses. We postulated that glycosylation influences antigen recognition and subsequently humoral responses to therapeutic antibodies by modulating 1) recognition and uptake by dendritic cells (DCs), and 2) antigen routing, processing and presentation. Here, we compared different glycosylation variants of the antibody rituximab (RTX) in in vitro assays using human DCs and T cells as well as in in vivo studies. We found that human DCs bind and internalize unmodified RTX stronger compared to its aglycosylated form suggesting that glycosylation mediates uptake after recognition by glycan-specific receptors. Furthermore, we show that DC-uptake of RTX increases or decreases if glycosylation is selectively modified to recognize activating (by mannosylation) or inhibitory lectin receptors (by sialylation). Moreover, glycosylation seems to influence antigen presentation by DCs because specific glycovariants tend to induce either stronger or weaker T cell activation. Finally, we demonstrate that antibody glycosylation impacts anti-drug antibody (ADA) responses to RTX in vivo. Hence, defined glycan structures can modulate immune recognition and alter ADA responses. Glyco-engineering may help to decrease clinical immunogenicity and ADA-associated adverse events such as hypersensitivity reactions.

Interest & Impact

Downloads

117 since deposited on 14 Apr 2022
66 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item